12-Oxocalanolide ACAS# 161753-49-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 161753-49-7 | SDF | Download SDF |
PubChem ID | 463613 | Appearance | Yellow powder |
Formula | C22H24O5 | M.Wt | 368.43 |
Type of Compound | Coumarins | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CCCC1=CC(=O)OC2=C1C3=C(C=CC(O3)(C)C)C4=C2C(=O)C(C(O4)C)C | ||
Standard InChIKey | HQVBDUZROQMWRN-VXGBXAGGSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 12-Oxocalanolide A is an inhibitor of HIV-1 reverse transcriptase (RT) and exhibits activity against a variety of viruse selected for resistance to other HIV-1 nonnucleoside RT inhibitors. |
Targets | HIV |
12-Oxocalanolide A Dilution Calculator
12-Oxocalanolide A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7142 mL | 13.5711 mL | 27.1422 mL | 54.2844 mL | 67.8555 mL |
5 mM | 0.5428 mL | 2.7142 mL | 5.4284 mL | 10.8569 mL | 13.5711 mL |
10 mM | 0.2714 mL | 1.3571 mL | 2.7142 mL | 5.4284 mL | 6.7855 mL |
50 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.0857 mL | 1.3571 mL |
100 mM | 0.0271 mL | 0.1357 mL | 0.2714 mL | 0.5428 mL | 0.6786 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- GLP-1 (9-36) amide
Catalog No.:BCC6001
CAS No.:161748-29-4
- Rasagiline mesylate
Catalog No.:BCN2166
CAS No.:161735-79-1
- Tebipenempivoxil
Catalog No.:BCC3861
CAS No.:161715-24-8
- Tebipenem
Catalog No.:BCC5550
CAS No.:161715-21-5
- Z-Ile-Leu-aldehyde
Catalog No.:BCC5591
CAS No.:161710-10-7
- Vincamine
Catalog No.:BCN2606
CAS No.:1617-90-9
- Lupenone
Catalog No.:BCN1717
CAS No.:1617-70-5
- Lupeol acetate
Catalog No.:BCN6893
CAS No.:1617-68-1
- Amentoflavone
Catalog No.:BCN6283
CAS No.:1617-53-4
- 2,3,8-Tri-O-methylellagic acid
Catalog No.:BCN1716
CAS No.:1617-49-8
- Caesalpine B
Catalog No.:BCN7377
CAS No.:1616757-60-8
- Caesalpine A
Catalog No.:BCN7376
CAS No.:1616757-59-5
- Palmatrubine
Catalog No.:BCN2647
CAS No.:16176-68-4
- Esomeprazole Sodium
Catalog No.:BCC4376
CAS No.:161796-78-7
- Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate
Catalog No.:BCC8969
CAS No.:161797-99-5
- Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate
Catalog No.:BCC8968
CAS No.:161798-01-2
- Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate
Catalog No.:BCC8966
CAS No.:161798-02-3
- Benzamil
Catalog No.:BCC7674
CAS No.:161804-20-2
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Talampanel(LY300164)
Catalog No.:BCC6378
CAS No.:161832-65-1
- Segetalin A
Catalog No.:BCC9246
CAS No.:161875-97-4
- Prehelminthosporol
Catalog No.:BCN7447
CAS No.:1619-13-2
- Esomeprazole Magnesium
Catalog No.:BCC5007
CAS No.:161973-10-0
- Catechin pentaacetate
Catalog No.:BCN1718
CAS No.:16198-01-9
Quantification of (+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human.[Pubmed:10901131]
J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):267-75.
A HPLC method was validated for quantification of (+)-calanolide A (1), a novel anti-HIV agent, in rat, dog and human plasma. The synthetic intermediate (+/-)-12-Oxocalanolide A (2) was found to be a suitable internal standard. Compounds were extracted from plasma using a solid-phase C(18) cartridge and quantified over the assay range of 12.5 to 800 ng/ml. The method was utilized to determine (+)-calanolide A pharmacokinetics in rats, dogs and humans. This is the first report of a validated HPLC assay for determination of (+)-calanolide A concentrations in rat and dog plasma as well as human plasma obtained from clinical trials. There was no evidence of in vivo epimerization of (+)-calanolide A to its inactive epimer (+)-calanolide B (3).
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.[Pubmed:9873509]
Bioorg Med Chem Lett. 1998 Aug 18;8(16):2179-84.
The three chromanone derivatives, (+)-, (-)-, and (+/-)-12-Oxocalanolide A (2), were evaluated for in vitro antiviral activities against HIV and simian immunodeficiency virus (SIV). The compounds were determined to be inhibitors of HIV-1 reverse transcriptase (RT) and exhibited activity against a variety of viruses selected for resistance to other HIV-1 nonnucleoside RT inhibitors. They are the first reported calanolide analogues capable of inhibiting SIV.